Key features and details
- Rabbit polyclonal to BIT1
- Suitable for: WB, IHC-P, ICC/IF
- Reacts with: Mouse, Human
- Isotype: IgG
Product nameAnti-BIT1 antibody
See all BIT1 primary antibodies
DescriptionRabbit polyclonal to BIT1
Tested applicationsSuitable for: WB, IHC-P, ICC/IFmore details
Species reactivityReacts with: Mouse, Human
Synthetic peptide corresponding to Human BIT1 (internal sequence).
(Peptide available as
- Daudi cell lysate. Human small intestine tissue.
This product was previously labelled as PTRH2
Storage instructionsShipped at 4°C. Store at +4°C.
Storage bufferPreservative: 0.02% Sodium azide
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab62554 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 1 - 2 µg/ml. Detects a band of approximately 20 kDa (predicted molecular weight: 20 kDa).|
|IHC-P||Use a concentration of 10 µg/ml.|
|ICC/IF||Use a concentration of 20 µg/ml.|
FunctionThe natural substrate for this enzyme may be peptidyl-tRNAs which drop off the ribosome during protein synthesis.
Promotes caspase-independent apoptosis by regulating the function of two transcriptional regulators, AES and TLE1.
Sequence similaritiesBelongs to the PTH2 family.
- Information by UniProt
- Bcl 2 inhibitor of transcription 1 antibody
- Bcl-2 inhibitor of transcription 1 antibody
- BIT 1 antibody
Lane 1 : Anti-BIT1 antibody (ab62554) at 1 µg/ml
Lane 2 : Anti-BIT1 antibody (ab62554) at 2 µg/ml
Lane 3 : Anti-BIT1 antibody (ab62554) at 4 µg/ml
All lanes : Daudi cell lysate
Lysates/proteins at 15 µg per lane.
Predicted band size: 20 kDa
Observed band size: 20 kDa
ab62554, at 10µg/ml, staining BIT1 in human small intestine by immunohistochemistry using paraffin-embedded tissue.
Immunofluorescence of Bit1 in Human Small Intestine cells using ab62554 at 20 ug/ml.
ab62554 has not yet been referenced specifically in any publications.